Daniel Weintraub

Neurology · Movement Disorders · 2006–2021

A researcher in the Science corpus: 14 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Neurology — 167 citations into it

Whom Daniel Weintraub trusts

Their strongest outbound trust, strongest first, inferred from their citations.

1. Dag Aarsland (in Neurology)

Papers from Daniel Weintraub's perspective

Ordered by how strongly the researchers Daniel Weintraub trusts endorse each paper. Same corpus, a different order for every researcher.

1. Clinical diagnostic criteria for dementia associated with Parkinson's disease (Movement Disorders)
2. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years (Movement Disorders)
3. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. (Journal of Clinical Psychiatry)
4. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. (Archives of Neurology)
5. MDS Task Force on Mild Cognitive Impairment in Parkinson’s disease: Critical Review of PD-MCI (Movement Disorders)
6. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. (The Lancet)
7. MDS clinical diagnostic criteria for Parkinson's disease (Movement Disorders)
8. Cognitive profile of patients with newly diagnosed Parkinson disease (Neurology)
9. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (Movement Disorders)
10. Metabolic brain networks associated with cognitive function in Parkinson's disease (NeuroImage)

Their papers

• Parkinson disease-associated cognitive impairment (2021) — 884 citations
• Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review (2019) — 866 citations
• Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated (2018) — 627 citations
• The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) — 595 citations
• Diagnosis and management of dementia with Lewy bodies (2017) — 2,290 citations
• Past, Present, and Future of Parkinson’s Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy (2017) — 734 citations
• Cognitive decline in Parkinson disease (2017) — 954 citations
• Diagnostic Criteria for Mild Cognitive Impairment in Parkinson’s Disease: Movement Disorder Society Task Force Guidelines (2012) — 2,505 citations
• The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease (2011) — 1,099 citations
• MDS Task Force on Mild Cognitive Impairment in Parkinson’s disease: Critical Review of PD-MCI (2011) — 784 citations
• Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. (2010) — 1,443 citations
• Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease (2009) — 1,183 citations
• Depression rating scales in Parkinson's disease: Critique and recommendations (2007) — 683 citations
• Association of dopamine agonist use with impulse control disorders in Parkinson disease. (2006) — 660 citations